TCIM
OVID icon

TIAA CREF Investment Management’s Ovid Therapeutics OVID Stock Holding History

TIAA CREF Investment Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$44K Buy
24,810
+1,741
+8% +$4.35K ﹤0.01% 2993
2018
Q4 		$56K Hold
23,069
– – ﹤0.01% 2995
2018
Q3 		$131K Sell
23,069
-2,374
-9% -$18K ﹤0.01% 3023
2018
Q2 		$198K Buy
25,443
+8,554
+51% +$73.4K ﹤0.01% 3037
2018
Q1 		$119K Hold
16,889
– – ﹤0.01% 3007
2017
Q4 		$167K Buy
16,889
+2,196
+15% +$20.2K ﹤0.01% 3015
2017
Q3 		$126K Buy
14,693
+1,132
+8% +$9.43K ﹤0.01% 3062
2017
Q2 		$142K Buy
+13,561
New +$177K ﹤0.01% 3098

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TIAA CREF Investment Management's OVID Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Ovid Therapeutics (OVID) stake by 7.5% in Q1 2019, buying an estimated $4.35K and bringing the position to 24,810 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #2993.

TIAA CREF Investment Management first reported a position in OVID in Q2 2017 and has held it in 8 quarters since. The position peaked at $198K in Q2 2018. 50 funds tracked by Wall St. Rank hold OVID as of Q1 2019.

  • TIAA CREF Investment Management held 24,810 shares of Ovid Therapeutics worth $44K as of Q1 2019.
  • TIAA CREF Investment Management bought 1,741 Ovid Therapeutics shares in Q1 2019, an estimated $4.35K.
  • Ovid Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2993 holding.
  • TIAA CREF Investment Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 8 quarters since.
  • TIAA CREF Investment Management's Ovid Therapeutics position peaked at $198K in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.